U.S. Markets closed

Aradigm Corporation (ARDM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.96+0.46 (+30.67%)
At close: 3:59PM EDT

2.08 +0.12 (6.12%)
After hours: 4:40PM EDT

People also watch

Aradigm Corporation

3929 Point Eden Way
Hayward, CA 94545
United States

IndustryDrug Delivery
Full Time Employees23

Key Executives

Dr. Igor Gonda Ph.D.Chief Exec. Officer, Pres and Exec. Director438.68kN/A69
Ms. Nancy E. PecotaChief Financial Officer, VP of Fin. and Corp. Sec.359.26kN/A57
Dr. Juergen Froehlich M.D., MBA, FCPhChief Medical Officer424.17kN/A60
Dr. Robert A. Reed Ph.D.VP of Regulatory CMC & QualityN/AN/A56
Dr. David Cipolla Ph.D.VP of Preclinical R&DN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. The company’s lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq (ARD-3150) and Lipoquin (ARD-3100) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis and cystic fibrosis. It is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, as well as the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever, and inhaled anthrax. The company has collaboration agreements with Oregon State University and Grifols, S.A. Aradigm Corporation was founded in 1991 and is headquartered in Hayward, California.

Corporate Governance

Aradigm Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.